TY - JOUR
T1 - Comparison of the cardiac electrophysiologic effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischaemia
AU - McIntosh, M. A.
AU - Tanira, M.
AU - Pacini, D.
AU - Kane, K. A.
PY - 1994
Y1 - 1994
N2 - The electrophysiologic effects of a new anti-arrhythmic agent NE-10064 were compared with known class III drugs, E-4031 and sotalol, in sheep Purkinje fibres paced at 1 Hz under normal and simulated ischaemic conditions. NE-10064 0.3-3 μM and sotalol 0.3-300 μM prolonged action potential duration at 90% of repolarization (APD90) and effective refractory period (ERP) concentration dependently without affecting APD50 under normal conditions. E-4031 0.3-300 μM prolonged APD50, APD90, and ERP concentration dependently. Percentage increases in APD90 of 20 ± 6, 27 ± 6, and 33 ± 9 were calculated for NE-10064 3 μM, sotalol 300 μM, and E- 4031 1 μM under normal conditions, respectively. The concentration-response curves for all three drugs were shifted to the right under simulated ischaemic conditions. The shift was more marked for NE-10064 and sotalol. Percentage increases in APD90 of 8 ± 5, 13 ± 2, and 23 ± 4 were observed with NE-10064 3 μM, sotalol 300 μM, and E-4031 1 μM during simulated ischaemia. NE-10064 exhibits electrophysiologic characteristics similar to those of known class III agents. Its ability to prolong APD90 under normal conditions may explain its antiarrhythmic action in vivo.
AB - The electrophysiologic effects of a new anti-arrhythmic agent NE-10064 were compared with known class III drugs, E-4031 and sotalol, in sheep Purkinje fibres paced at 1 Hz under normal and simulated ischaemic conditions. NE-10064 0.3-3 μM and sotalol 0.3-300 μM prolonged action potential duration at 90% of repolarization (APD90) and effective refractory period (ERP) concentration dependently without affecting APD50 under normal conditions. E-4031 0.3-300 μM prolonged APD50, APD90, and ERP concentration dependently. Percentage increases in APD90 of 20 ± 6, 27 ± 6, and 33 ± 9 were calculated for NE-10064 3 μM, sotalol 300 μM, and E- 4031 1 μM under normal conditions, respectively. The concentration-response curves for all three drugs were shifted to the right under simulated ischaemic conditions. The shift was more marked for NE-10064 and sotalol. Percentage increases in APD90 of 8 ± 5, 13 ± 2, and 23 ± 4 were observed with NE-10064 3 μM, sotalol 300 μM, and E-4031 1 μM during simulated ischaemia. NE-10064 exhibits electrophysiologic characteristics similar to those of known class III agents. Its ability to prolong APD90 under normal conditions may explain its antiarrhythmic action in vivo.
KW - Class III antiarrhythmic drugs
KW - Electrophysiology
KW - NE-10064
KW - Simulated ischaemia
UR - http://www.scopus.com/inward/record.url?scp=0028208260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028208260&partnerID=8YFLogxK
U2 - 10.1097/00005344-199404000-00020
DO - 10.1097/00005344-199404000-00020
M3 - Article
C2 - 7516018
AN - SCOPUS:0028208260
SN - 0160-2446
VL - 23
SP - 653
EP - 657
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
IS - 4
ER -